Newer Blood Thinners Linked to Slower Cognitive Decline in Alzheimer’s Patients
- Newer blood thinners may do more than prevent strokes in older adults, according to recent medical research examining patients with Alzheimer’s disease and atrial fibrillation.
- The study drew on nationwide registry data from Sweden, examining 7,308 people diagnosed with both Alzheimer's disease and pre-existing atrial fibrillation.
- Patients treated with NOACs showed a significantly slower decline on their Mini-Mental State Examination scores over the course of the tracking period.
Newer blood thinners may do more than prevent strokes in older adults, according to recent medical research examining patients with Alzheimer’s disease and atrial fibrillation. Investigators found that individuals taking novel oral anticoagulants experienced a slower rate of cognitive decline compared to those treated with older medications or no blood thinners at all, pointing to a potential secondary benefit for brain health in vulnerable patient groups.
Evaluating Cognitive Decline in Patients With Atrial Fibrillation
The study drew on nationwide registry data from Sweden, examining 7,308 people diagnosed with both Alzheimer’s disease and pre-existing atrial fibrillation. Participants had an average age of 82.6 years at their Alzheimer’s diagnosis, and slightly more than half of the cohort were women. Researchers utilized data from SveDem, the Swedish Register for Cognitive Disorders/Dementia, linking those records with national health registers covering diagnoses, prescriptions, deaths, and clinical outcomes.
To track changes over time, the research team used the Mini-Mental State Examination, a standard tool that measures thinking, memory, and orientation. Participants were split into three matched groups based on their treatment regimens: those using newer oral anticoagulants, known as NOACs; those using the older blood thinner warfarin; and a third group taking no anticoagulant medication whatsoever.
Comparing Blood Thinner Options and Memory Scores
Patients treated with NOACs showed a significantly slower decline on their Mini-Mental State Examination scores over the course of the tracking period. The difference measured just over 0.2 points per year when compared against patients taking warfarin or receiving no anticoagulant therapy. While that margin appears small on an annual basis, researchers noted that the divergence accumulates over a multi-year period.
While annual changes for a single person may appear minimal, an impact of this magnitude can ultimately shape how mental capabilities evolve over an extended timeframe. Our findings suggest that NOAC treatment may also be significant for cognition in this patient group.
Nanbo Zhu, Karolinska Institutet
After five years of observation, estimated test scores remained higher among participants using NOACs than among individuals in the other two study groups.
Understanding Potential Mechanisms Behind the Findings
Atrial fibrillation is a frequent irregular heartbeat condition among older adults that can cause blood clots and elevate stroke risks, prompting doctors to prescribe blood thinners. Because many older patients live with both this cardiac condition and Alzheimer’s disease, clinicians frequently face complex treatment decisions.
Investigators see grounds to believe this therapy could benefit mental faculties by, for instance, enhancing circulation and mitigating minor neurological injury.
Maria Eriksdotter, Karolinska Institutet
Eriksdotter, who led the study and serves as a senior consultant in geriatric medicine at Karolinska University Hospital, emphasized that the observational design means the research cannot definitively prove that NOACs directly protect brain tissue. Because investigators followed real-world patients rather than assigning treatments through a randomized clinical trial, further controlled investigations will be required to confirm whether the drugs themselves actively slow cognitive loss.